NCT02137772View on ClinicalTrials.gov

Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)

PHASE3CompletedINTERVENTIONAL

Enrollment

570

Participants

Timeline

Start Date

June 6, 2014

Primary Completion Date

August 8, 2016

Study Completion Date

November 21, 2016

Conditions

Prevention of CMV Infection or Disease

Interventions

DRUG

Letermovir

Letermovir 240 mg / 480 mg tablets, or 240 mg / 480 mg intravenous solution in 250 mL to be infused over 60 minutes.

DRUG

Placebo

Placebo tablets, or intravenous solution in 250 mL to be infused over 60 minutes.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02137772 - Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) | Biotech Hunter | Biotech Hunter